For The Better

Dividend stocks are more critical than ever to producing long-term portfolio gains.

Patient investors should come out ahead with these stocks.

ShockWave, Vir, and BioCryst are all seeing skyrocketing sales this quarter.

Cranking out new medicines is business as usual, but these three could be big earners.

Coca-Cola has proved time and again that it can face down the bears and bounce back from recessions.

By making some smart moves now (and later), you can increase your benefits.

Qualcomm stock looks attractive on many levels, but one aspect of its revenue stream may give investors pause.

The innovative technology just never gained enough traction.

The company has excellent prospects in the near term as economies reopen worldwide.

The stock of the most dominant asset manager in the world has tumbled recently due to the broader market’s downturn.

Investors think PayPal’s business is hurting but it’s being downloaded as much as ever.

A small 3M subsidiary is engaged in a legal battle with military veterans that could lead to a huge liability.

Alphabet’s past investments in diversification paid off in the second quarter of 2022.

A few minutes a year can save you a lot of money.

These nominal prices have begun to look high amid the Amazon and Alphabet splits.

This stock is seeing huge success.

The real question may be, has Abbott been a better buy than AbbVie since the spinoff?

Two great companies, both alike in dignity, in fair Silicon Valley, where we lay our scene, are poised to bounce back from today’s deep stock market discounts.

By leaning into sustainability, these three companies are laying the groundwork for a bright future.

These two companies haven’t performed well in the market recently, but that could be an opportunity for investors.